The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major
development in the last decade. The indications for ICIs are constantly expanding into new …

Abstract Treatment of patients with hepatocellular carcinoma (HCC) in the advanced stage
remains a great challenge, with very few drugs approved. After decades of failure of immune …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Purpose of review The systemic treatment of advanced hepatocellular carcinoma (HCC) has
significantly evolved. Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy …

Multikinase inhibitors with antiangiogenic properties used to be standard therapy for patients
with advanced hepatocellular carcinoma (HCC). Recently, several antiangiogenic agents …

Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually
diagnosed in advanced stages due to late symptom manifestation with very limited …

Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed
markedly. Although sorafenib was used in clinical practice as the first molecular targeted …

According to the 2020 European Society for Medical Oncology (ESMO) guidelines, three
different therapeutic options are currently available as first-line treatment for patients with …

Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …